182181-42-6

Basic information

• Product Name: 2-Chloromethyl-8-methyl-imidazo[1,2-a]pyridine
• Synonyms: Imidazo[1,2-a]pyridine, 2-(chloromethyl)-8-methyl- (9CI);2-(chloromethyl)-8-methylimidazo[1,2-a]pyridine(SALTDATA: HCl 0.87H2O);2-(chloromethyl)-8-methylimidazo[1,2-a]pyridine HCl 0.87H2O;IMidazo[1,2-a]pyridine, 2-(chloroMethyl)-8-Methyl-
• CAS NO: 182181-42-6
• Molecular Formula: C₉H₉ClN₂
• Molecular Weight: 180.63416
• Product Categories: HALOMETYL
• Mol File: 182181-42-6.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 2-Chloromethyl-8-methyl-imidazo[1,2-a]pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Chloromethyl-8-methyl-imidazo[1,2-a]pyridine(182181-42-6)
• EPA Substance Registry System: 2-Chloromethyl-8-methyl-imidazo[1,2-a]pyridine(182181-42-6)

Safety Data

• Hazardous Substances Data: 182181-42-6(Hazardous Substances Data)

Usage

General Description

2-Chloromethyl-8-methyl-imidazo[1,2-a]pyridine, also known as 8-chloromethyl-2-methylimidazo[1,2-a]pyridine, is a chemical compound with the molecular formula C9H8ClN3. It is a heterocyclic aromatic compound that is commonly used in the synthesis of pharmaceuticals and agrochemicals. This chemical has been identified as a potential carcinogen and mutagen, and has been found in tobacco smoke and grilled or charred meat. It is important to handle and use this chemical with caution and under proper safety measures to mitigate any potential health risks associated with its use.

Upstream product

• 1603-40-3 3-methylpyridin-2-ylamine 
• 534-07-6 1,3-Dichloroacetone 

Relevant articles and documents

TRIAZOLO- AND PYRAZOLOQUINAZOLINE DERIVATIVES AS PDE10A ENZYME INHIBITOR

The invention relates to compounds of the formula (I) and their use as pharmaceutical ingredients, in particular for the treatment of CNS related diseases.

NOVEL PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS

This invention is directed to compounds, which are PDE10A enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula I. The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention also provides a method of treating a subject suffering from a drug addiction comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I.

NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS

The present invention relates to novel compounds of formula (I) wherein W, n, X and W’ are defined in the description; invention compounds are modulators of metabotropic glutamate receptors - subtype 5 (“mGluR5”) which are useful for the treatment of central nervous system disorders as well as other disorders modulated by mGluR5 receptors.